| pubmed-article:20561180 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:20561180 | lifeskim:mentions | umls-concept:C0008976 | lld:lifeskim |
| pubmed-article:20561180 | lifeskim:mentions | umls-concept:C0025219 | lld:lifeskim |
| pubmed-article:20561180 | lifeskim:mentions | umls-concept:C0751772 | lld:lifeskim |
| pubmed-article:20561180 | lifeskim:mentions | umls-concept:C0205228 | lld:lifeskim |
| pubmed-article:20561180 | pubmed:issue | 4 | lld:pubmed |
| pubmed-article:20561180 | pubmed:dateCreated | 2010-10-27 | lld:pubmed |
| pubmed-article:20561180 | pubmed:abstractText | Rapid eye movement (REM) sleep behaviour disorder (RBD) has been suggested to predict the development of neurodegenerative disorders. Patients with RBD are acting out dream behaviour associated with loss of normal muscle atonia of REM sleep. The aim of the present study was to confirm that exogenous melatonin improves RBD. Eight consecutively recruited males (mean age 54 years) with a polysomnographically (PSG) confirmed diagnosis of RBD were included in a two-part, randomized, double-blind, placebo-controlled cross-over study. Patients received placebo and 3 mg of melatonin daily in a cross-over design, administered between 22:00 h and 23:00 h over a period of 4 weeks. PSG recordings were performed in all patients at baseline, at the end of Part I of the trial and at the end of Part II of the trial. Compared to baseline, melatonin significantly reduced the number of 30-s REM sleep epochs without muscle atonia (39% versus 27%; P = 0.012), and led to a significant improvement in clinical global impression (CGI: 6.1 versus 4.6; P = 0.024). Interestingly, the number of REM sleep epochs without muscle atonia remained lower in patients who took placebo during Part II after having received melatonin in Part I (-16% compared to baseline; P = 0.043). In contrast, patients who took placebo during Part I showed improvements in REM sleep muscle atonia only during Part II (i.e. during melatonin treatment). The data suggest that melatonin might be a second useful agent besides clonazepam in the treatment of RBD. | lld:pubmed |
| pubmed-article:20561180 | pubmed:language | eng | lld:pubmed |
| pubmed-article:20561180 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20561180 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:20561180 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20561180 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20561180 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:20561180 | pubmed:month | Dec | lld:pubmed |
| pubmed-article:20561180 | pubmed:issn | 1365-2869 | lld:pubmed |
| pubmed-article:20561180 | pubmed:author | pubmed-author:KunzDieterD | lld:pubmed |
| pubmed-article:20561180 | pubmed:author | pubmed-author:MahlbergRicha... | lld:pubmed |
| pubmed-article:20561180 | pubmed:copyrightInfo | © 2010 European Sleep Research Society. | lld:pubmed |
| pubmed-article:20561180 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:20561180 | pubmed:volume | 19 | lld:pubmed |
| pubmed-article:20561180 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:20561180 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:20561180 | pubmed:pagination | 591-6 | lld:pubmed |
| pubmed-article:20561180 | pubmed:meshHeading | pubmed-meshheading:20561180... | lld:pubmed |
| pubmed-article:20561180 | pubmed:meshHeading | pubmed-meshheading:20561180... | lld:pubmed |
| pubmed-article:20561180 | pubmed:meshHeading | pubmed-meshheading:20561180... | lld:pubmed |
| pubmed-article:20561180 | pubmed:meshHeading | pubmed-meshheading:20561180... | lld:pubmed |
| pubmed-article:20561180 | pubmed:meshHeading | pubmed-meshheading:20561180... | lld:pubmed |
| pubmed-article:20561180 | pubmed:meshHeading | pubmed-meshheading:20561180... | lld:pubmed |
| pubmed-article:20561180 | pubmed:meshHeading | pubmed-meshheading:20561180... | lld:pubmed |
| pubmed-article:20561180 | pubmed:meshHeading | pubmed-meshheading:20561180... | lld:pubmed |
| pubmed-article:20561180 | pubmed:meshHeading | pubmed-meshheading:20561180... | lld:pubmed |
| pubmed-article:20561180 | pubmed:meshHeading | pubmed-meshheading:20561180... | lld:pubmed |
| pubmed-article:20561180 | pubmed:meshHeading | pubmed-meshheading:20561180... | lld:pubmed |
| pubmed-article:20561180 | pubmed:meshHeading | pubmed-meshheading:20561180... | lld:pubmed |
| pubmed-article:20561180 | pubmed:meshHeading | pubmed-meshheading:20561180... | lld:pubmed |
| pubmed-article:20561180 | pubmed:year | 2010 | lld:pubmed |
| pubmed-article:20561180 | pubmed:articleTitle | A two-part, double-blind, placebo-controlled trial of exogenous melatonin in REM sleep behaviour disorder. | lld:pubmed |
| pubmed-article:20561180 | pubmed:affiliation | Institute of Physiology, Charité, Campus Benjamin Franklin, Universitätsmedizin Berlin, Berlin, Germany. dieter.kunz@charite.de | lld:pubmed |
| pubmed-article:20561180 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:20561180 | pubmed:publicationType | Randomized Controlled Trial | lld:pubmed |
